ABCs Report: Neisseria meningitidis, 2017

April 5, 2019: Content on this page kept for historical reasons.

Active Bacterial Core Surveillance (ABCs): Emerging Infections Program Network

Print-friendly version of this surveillance report Cdc-pdf[1 page]

Surveillance Note

Missing race (n=6) data were multiply imputed using sequential regression imputation methods.

ABCs Areas

California (3 county San Francisco Bay area); Colorado (5 county Denver area); Connecticut; Georgia; Maryland; Minnesota; New Mexico; New York (15 county Rochester and Albany areas); Oregon; Tennessee (20 counties)

ABCs Population

The surveillance areas represent 44,593,843 persons.

Source: National Center for Health Statistics bridged race vintage 2017 postcensal file

ABCs Case Definition

Meningococcal disease: isolation of Neisseria meningitidis from normally sterile site in a resident of a surveillance area in 2017.

ABCs Methodology

ABCs personnel routinely contacted all microbiology laboratories serving acute care hospitals in their area to identify cases. Standardized case report forms that include information on demographic characteristics, clinical syndrome, and outcome of illness were completed for each identified case. Serogrouping of meningococcal isolates was done at CDC and state laboratories. Regular laboratory audits assessed completeness of active surveillance and detected additional cases.

All rates of meningococcal disease were calculated using population estimates for 2017 from the bridged-race vintage 2017 postcensal file. For national estimates of cases and deaths, race- and age specific rates of disease were applied from the aggregate surveillance area to the age and racial distribution of the 2017 U.S. population for 49 states (excluding Oregon due to higher reported incidence rates of serogroup B and overall meningococcal disease). The Oregon reported cases were then added to obtain the national estimates. Cases with missing data, excluding ethnicity, were multiply imputed using sequential regression imputation methods.

Reported ABCs Profiles

Race No. (Rate*)
White 41 (0.13)
Black 15 (0.18)
Other 2 (0.05)
Total 58 (0.13)

* Per 100,000 population for ABCs areas

Syndrome Cases
No. (%*)
Deaths
No. (Rate)
Meningitis 21 (36.2) 3 (14.3)
Bacteremia without focus 17 (29.3) 1 (6.3)

* Percent of cases
Per 100 cases with known outcome

Age (years) Serogroup B
No. (Rate*)
Serogroup C
No. (Rate*)
Serogroup Y
No. (Rate*)
Serogroup Other
No. (Rate*)
< 1 0 (0.00) 0 (0.00) 1 (0.21) 3 (0.62)
1 1 (0.21) 0 (0.00) 0 (0.00) 0 (0.00)
2-4 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
5-17 2 (0.03) 0 (0.00) 0 (0.00) 0 (0.00)
18-34 0 (0.00) 0 (0.00) 0 (0.00) 3 (0.03)
35-49 0 (0.00) 4 (0.05) 2 (0.03) 0 (0.00)
50-64 2 (0.03) 1 (0.01) 1 (0.01) 3 (0.04)
65-74 1 (0.03) 1 (0.03) 1 (0.03) 2 (0.06)
75-84 1 (0.06) 3 (0.18) 2 (0.12) 2 (0.12)
≥ 85 1 (0.13) 0 (0.00) 1 (0.13) 0 (0.00)
Total 8 (0.02) 9 (0.02) 8 (0.02) 13 (0.03)

*Per 100,000 population for ABCs areas excluding Oregon

† Unknown serogroup (n=2) distributed amongst known.
All rates exclude Oregon. Rates including Oregon are serogroup B 0.03, serogroup C 0.05, serogroup Y 0.02, and serogroup Other 0.03 per 100,000 population for ABCs areas.

‡ Other includes serogroup W and nongroupables

Rates of Meningococcal Disease in Adolescents and Young Adults

Age (years) Overall Serogroups
No. (Rate*)
C/Y/W Serogroups
No. (Rate*)
11-17 1 (0.03) 0 (0.00)
18-22 1 (0.04) 1 (0.04)

* Per 100,000 population for ABCs areas excluding Oregon
† All rates exclude Oregon. Rates including Oregon are, for 11-17 year olds, overall serogroups 0.03 and serogroup C/Y/W 0.00; for 18-22 year olds, overall serogroups 0.14 and serogroup C/Y/W 0.03 per 100,000 population for ABCs areas

National Estimates for Disease¥

Cases: 310 (0.10/100,000)
Deaths: 40 (0.01/100,000)

¥ In 2017, 349 cases of meningococcal disease (confirmed and probable) were reported to the National Notifiable Disease Surveillance System, resulting in an incidence of 0.11/100,000 population. For additional information on national incidence, please view our Enhanced Meningococcal Disease Surveillance Report Cdc-pdf[2 pages].

Healthy People 2020 Update

Objective: Reduce the incidence of meningococcal disease to 0.3 per 100,000 population.

2020 Objective 2017 Rate*
0.3/100,000 0.10/100,000

* Per 100,000 U.S. population

Citation

Centers for Disease Control and Prevention. 2017.  Active Bacterial Core Surveillance Report, Emerging Infections Program Network,  Neisseria meningitidis, 2017.

 Top of Page

View Page In:Cdc-pdf
Page last reviewed: April 5, 2019 (archived document)